Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H34N4O5S |
| Molecular Weight | 502.626 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(C)=C(C(C)=C1)S(=O)(=O)N(C)CCOCC(=O)N(C)CC2=CC=C(C=C2)C3=NCCN3
InChI
InChIKey=AMTQCENHQIDBHQ-UHFFFAOYSA-N
InChI=1S/C25H34N4O5S/c1-18-14-22(33-5)15-19(2)24(18)35(31,32)29(4)12-13-34-17-23(30)28(3)16-20-6-8-21(9-7-20)25-26-10-11-27-25/h6-9,14-15H,10-13,16-17H2,1-5H3,(H,26,27)
Safotibant (previously known as LF22-0542) was developed as an antagonist at bradykinin B1 receptor for the topical treatment of diabetic macular edema. This drug participated in phase II clinical trials in Australia, in Belgium and in the Czech Republic. However, further, development was discontinued.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist. | 2006 Jul |
|
| Role of kinin B1 and B2 receptors in a rat model of neuropathic pain. | 2008 Feb |
|
| Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats. | 2012 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 21:16:39 GMT 2023 , Edited by admin on Fri Dec 15 21:16:39 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C152283
Created by
admin on Fri Dec 15 21:16:39 GMT 2023 , Edited by admin on Fri Dec 15 21:16:39 GMT 2023
|
PRIMARY | |||
|
300000034400
Created by
admin on Fri Dec 15 21:16:39 GMT 2023 , Edited by admin on Fri Dec 15 21:16:39 GMT 2023
|
PRIMARY | |||
|
11953367
Created by
admin on Fri Dec 15 21:16:39 GMT 2023 , Edited by admin on Fri Dec 15 21:16:39 GMT 2023
|
PRIMARY | |||
|
DTXSID20212769
Created by
admin on Fri Dec 15 21:16:39 GMT 2023 , Edited by admin on Fri Dec 15 21:16:39 GMT 2023
|
PRIMARY | |||
|
9479
Created by
admin on Fri Dec 15 21:16:39 GMT 2023 , Edited by admin on Fri Dec 15 21:16:39 GMT 2023
|
PRIMARY | |||
|
CHEMBL1254771
Created by
admin on Fri Dec 15 21:16:39 GMT 2023 , Edited by admin on Fri Dec 15 21:16:39 GMT 2023
|
PRIMARY | |||
|
Safotibant
Created by
admin on Fri Dec 15 21:16:39 GMT 2023 , Edited by admin on Fri Dec 15 21:16:39 GMT 2023
|
PRIMARY | |||
|
02HU8HWP7U
Created by
admin on Fri Dec 15 21:16:39 GMT 2023 , Edited by admin on Fri Dec 15 21:16:39 GMT 2023
|
PRIMARY | |||
|
633698-99-4
Created by
admin on Fri Dec 15 21:16:39 GMT 2023 , Edited by admin on Fri Dec 15 21:16:39 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
